Articles published by ObsEva SA
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Update on Board of Directors
March 19, 2024
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
Geneva Court Grants Temporary Moratorium to ObsEva
January 31, 2024
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Files half Year 2023 Financial Statements
September 27, 2023
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Recovers Full Worldwide Rights on Nolasiban
July 13, 2023
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Change of Central Securities Depositary
April 20, 2023
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Files Year End 2022 Financial Statements
March 31, 2023
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
March 13, 2023
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
February 24, 2023
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Dismissal of Moratorium Proceedings
December 19, 2022
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 14, 2022
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
December 01, 2022
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 26, 2022
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
October 13, 2022
From ObsEva SA
Via GlobeNewswire
Tickers
OBSV
![](https://ml-eu.globenewswire.com/media/f1aaffc3-afa9-43e4-8466-45fb87ea222f/small/obseva-logo-highresolution-jpg.jpg)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.